A daily GLP-1 pill cut body weight by up to 11.3% in 36 weeks

GLP-1 receptor agonist drugs have reshaped obesity treatment, and how a drug is made and taken shapes who can realistically use it. Aleniglipron is an oral, small-molecule GLP-1 receptor agonist in development for treating obesity, taken as a once-daily dose rather than by injection. The question for this mid-stage trial was straightforward: can a small-molecule pill produce clinically relevant weight loss with side effects people can tolerate, and at which doses? The answer determines whether the drug justifies expensive final-stage trials.

The ACCESS phase 2b trial randomly assigned 230 adults with obesity or overweight, with a mean BMI of 39.5 and 54% women, to once-daily aleniglipron or placebo for 36 weeks, with neither participants nor investigators knowing who received which. Doses were escalated every 4 weeks up to 45, 90 or 120 mg. The primary endpoint was the placebo-adjusted change in body weight from baseline at week 36, alongside safety and tolerability. An open-label extension continued afterwards, with an interim analysis at a median treatment duration of 20 weeks.

At week 36, placebo-adjusted weight loss was 8.2% on the 45 mg dose, 9.8% on 90 mg and 11.3% on 120 mg, all statistically significant, with no apparent plateau when the blinded period ended. Weight loss was still continuing at the interim look at the open-label extension. Gastrointestinal side effects were generally mild to moderate and became less frequent over time, with little to no recurrence of vomiting when dosing resumed after permitted interruptions. Treatment-related discontinuations ran at 10.4% across the aleniglipron arms, and there were no cases of drug-induced liver injury.

The authors describe the tolerability profile as consistent with the wider GLP-1 receptor agonist class and the weight reductions as clinically relevant, supporting further development. This remains a phase 2b result: mid-stage trials establish dose and promise, not approval, and the findings need confirming in larger and longer final-stage studies. Several authors are employees of the company developing the drug, which is standard at this stage but worth knowing. How the pill compares directly with existing options is a question this trial was not designed to answer.

If you have followed the GLP-1 story, this is evidence that a once-daily pill can deliver double-digit placebo-adjusted weight loss in a mid-stage trial, with weight still coming off at the 36-week mark. That is a reason to expect the range of options in this drug class to keep widening, though this particular drug is not an approved medicine and its long-term performance is unknown. Gut side effects remain part of the package, though here they eased over time. Nothing in a phase 2b result changes what anyone should do today.